Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fc?-Receptor Signaling Pathways

The expression of Triggering Receptor Expressed on Myeloid cells ( TREM)-1 has been described as a predictive marker for anti-Tumor Necrosis Factor (TNF)-? monoclonal antibody (mAb) therapy responsiveness in patients with inflammatory bowel disease (IBD). Here we investigated TREM-1 specifically CD14+ monocytes relation to anti-TNF response. pretreatment levels Crohn’s (CD) were outcome mAb therapy, low associated response anti-TNF. FACSorting different showed that differentiation towards regulatory CD206+ M2 type macrophages by was suppressed high expression. Activity the Fc?-Receptor and autophagy pathway, both necessary anti-TNF, decreased TREM-1. We confirmed activity pathway CD did not respond it negatively correlated patient cohort. In conclusion, our results indicate associate Fc?R resulting upon treatment, which may explain non-response IBD .